Prospective Sequential Biosample and Data Collection for the Study of Therapy Resistance in Melanoma (PROSEQ-DYNAMO)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037444

Enrollment

288

Registered

2025-07-16

Start date

2024-04-05

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Interventions

Group 1: Biosampling arm under standard systemic therapy for advanced, unresectable melanoma

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Melanoma patients at the Department of Dermatology (stages I to IV according to AJCC 2018) who are capable of giving consent, are scheduled to undergo systemic therapy, and have provided written informed consent.

Exclusion criteria

Exclusion criteria: - Patients unable to provide informed consent - Patients under 18 years of age - Pregnant and breastfeeding women - Missing or withdrawn consent

Design outcomes

Primary

Measure	Time frame
1-yr PFS	—

Countries

Germany

Contacts

Public ContactAlexander Rösch

Universitätsklinikum Essen, Klinik für Dermatologie

alexander.roesch@uk-essen.de02017234747

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026